,0,1
0,cell carcinoma,9.0
1,muscle disorders,9.0
2,standby letter,9.0
3,kidney disease,8.777777777777779
4,intellectual property,8.75
5,balance sheets,8.720349563046192
6,significant judgment,8.666666666666666
7,resource functions,8.625
8,accounting standards codification,8.50943396226415
9,natural regulators,8.5
10,retrospective application,8.464285714285715
11,protein engineering,8.434782608695652
12,balance sheets,8.371647509578544
13,legal proceedings,8.357142857142858
14,tax authorities,8.347153465346535
15,group,8.333333333333334
16,property position,8.333333333333334
17,claims,8.295652173913044
18,operating officer,8.208333333333334
19,regulatory approval,8.2
20,taxing authorities,8.2
21,innovative therapeutics,8.177884615384615
22,months,8.17740708817117
23,accounting policies,8.176100628930818
24,retrospective application,8.170168067226891
25,patient populations,8.166666666666666
26,september30,8.16469893742621
27,valuation allowance,8.134920634920636
28,accounting pronouncements,8.124818577648766
29,growth factor,8.114285714285714
30,months,8.090273363000636
31,future outcomes,8.087301587301587
32,estate taxes,8.035714285714285
33,tax positions,8.034653465346535
34,executive officer,8.017857142857142
35,regulatory approvals,8.0
36,year lease extension,7.999673202614379
37,holding gains,7.989130434782609
38,consolidated statements,7.981460674157303
39,unforeseen expenses,7.976958525345622
40,revenue service,7.942857142857143
41,revenue code,7.942857142857143
42,retrospective method,7.928104575163399
43,study materials,7.893518518518519
44,accounting policies,7.855587808417997
45,public offering,7.85531914893617
46,accounting policies,7.8427672955974845
47,stock unit,7.8237358101135195
48,trial failures,7.8165954415954415
49,additional funds,7.80911330049261
50,setting bodies,7.803921568627451
51,balance sheet risk,7.794346978557505
52,regulatory requirements,7.782978723404256
53,clinical trials,7.7809059059059065
54,investor relations,7.770588235294118
55,allowable investments,7.754545454545455
56,stock units,7.746812733190442
57,patent applications,7.717391304347826
58,operating requirements,7.716312056737589
59,recurring adjustments,7.714285714285714
60,harbor provisions,7.714285714285714
61,clinical trials,7.703982828982829
62,state laws,7.7
63,substantial doubt,7.695054945054945
64,partnership agreements,7.692982456140351
65,preferred stock,7.692156862745098
66,capital resources,7.683962264150944
67,standards,7.683098591549296
68,unobservable inputs,7.666666666666666
69,contract research organizations,7.63819095477387
70,therapeutic candidates,7.637142857142858
71,biologics licensing application,7.6309523809523805
72,reasons,7.625
73,balance sheet arrangements,7.590643274853801
74,data,7.583333333333333
75,therapeutic candidate,7.578571428571429
76,retrospective application,7.572393822393822
77,muscular dystrophy,7.571428571428571
78,december31,7.570030055817948
79,december31,7.570030055817948
80,call date,7.568181818181818
81,tax assets,7.566718682737839
82,productive discovery,7.564516129032258
83,toxicology studies,7.554545454545455
84,licensed products,7.532608695652174
85,lab space,7.516666666666667
86,financial statements,7.496153846153847
87,extension studies,7.493518518518519
88,letters,7.477852348993289
89,company,7.477852348993289
90,responsibility,7.477852348993289
91,luspatercept expired unexercised,7.477777777777778
92,consolidated statements,7.464219294846959
93,accounting standards,7.442767295597484
94,valuation allowance,7.430572808833678
95,payment accounting,7.428551609322975
96,accounting standards,7.39832285115304
97,retrospective basis,7.390092879256966
98,legal proceedings,7.357142857142858
99,drug supply expenses,7.343625192012289
100,financial statements,7.327614520311149
101,ten years,7.326086956521739
102,balance sheet date,7.325491759702286
103,services arrangement,7.32391304347826
104,milestone payment,7.310185185185185
105,interest rate,7.291666666666667
106,exercise price,7.273752012882448
107,payments,7.273595258999122
108,additional capital,7.243075564643554
109,phase2 trials,7.239035739035739
110,discovery stage compounds,7.231182795698924
111,public offering,7.23031914893617
112,operating losses,7.220657276995306
113,patent claims,7.217391304347826
114,offering price,7.203145235892691
115,regulatory approval,7.2
116,regulatory approval,7.2
117,preclinical studies,7.196153846153846
118,responsibility,7.192138063279003
119,facility lease obligations,7.171865715983364
120,capital requirements,7.150274320888532
121,interest income,7.142441860465116
122,lease arrangements,7.138888888888888
123,accounting guidance,7.134433962264151
124,unrealized gains,7.131987577639752
125,subsequent phase2,7.121489621489621
126,deferred revenue,7.10807453416149
127,operating costs,7.1039215686274515
128,aggregate change,7.065712426805465
129,balance sheet classification,7.057309941520468
130,trial data,7.049928774928775
131,licensed products,7.032608695652174
132,research organizations,7.031709473292388
133,deferred revenue,7.022948676037921
134,additional compounds,7.011494252873563
135,drug product,7.010185185185185
136,regulatory approvals,7.0
137,regulatory approvals,7.0
138,month term,6.982142857142858
139,therapeutic candidates,6.981970443349754
140,stock options,6.961204481792717
141,common stock,6.954761904761905
142,clinical trials,6.9475725725725725
143,additional capital,6.921646993214983
144,annual periods,6.900414078674949
145,backed securities,6.898989898989899
146,unvested options,6.898079877112135
147,financial statements,6.887458193979933
148,sublicensing revenue,6.887301587301588
149,therapeutic candidates,6.887142857142858
150,preferred stock,6.875255454294394
151,officer insurance premiums,6.875
152,rent escalations,6.871428571428572
153,clinical trials,6.8682074932074935
154,therapeutic candidates,6.859365079365079
155,comparative periods,6.858253799929304
156,valuation allowance,6.85113685113685
157,clinical trials,6.836461461461462
158,stock equivalents,6.814136904761905
159,exchange contracts,6.8125
160,loss position,6.811202506854681
161,company,6.811185682326622
162,tax benefits,6.795822880638888
163,tax attribute carryforwards,6.784653465346535
164,therapeutic candidates,6.766175115207374
165,equivalent balances,6.759776536312849
166,manufacturing processes,6.749032258064516
167,income tax provision,6.746539770256096
168,quarterly reports,6.742857142857143
169,additional financing,6.742263483642793
170,therapeutic candidates,6.733296703296704
171,financial assets,6.730876068376068
172,therapeutic candidates,6.724444444444445
173,identification method,6.722222222222222
174,funding requirements,6.720280310705842
175,additional debt,6.719827586206897
176,clinical trials,6.709477334477334
177,common stock,6.704761904761905
178,securities laws,6.698989898989899
179,therapeutic candidate,6.665873015873016
180,clinical studies,6.660185185185185
181,diluted equity,6.64935064935065
182,celgene collaborate,6.645911166459111
183,hedging arrangements,6.645833333333333
184,compensation expense,6.6457767772623075
185,costs,6.645588235294118
186,significant expenses,6.643625192012288
187,research institutions,6.63819095477387
188,research fee,6.63819095477387
189,potential amount,6.6362407031778226
190,state nol carryforwards,6.592857142857143
191,unrealized loss,6.581317449383416
192,therapeutic candidate,6.578571428571429
193,licensing expense,6.569114957084564
194,financial instruments,6.568376068376068
195,interim periods,6.563146997929607
196,ownership change,6.54559748427673
197,risks,6.525
198,interest income interest,6.517441860465116
199,royalty obligations,6.514745735692651
200,early adoption,6.514634146341464
201,cash equivalents,6.50073048368127
202,products,6.496894409937888
203,compensation awards,6.491361613138406
204,therapeutic candidates,6.4871428571428575
205,therapeutic candidates,6.480280112044818
206,credit risk,6.456864623243933
207,fasb issued asu,6.421066505987799
208,milestone payments,6.418203102136377
209,stock plan,6.411971104231166
210,exercise price,6.411683047365207
211,income tax expense,6.408891442316506
212,additional activities,6.400383141762452
213,tax benefits,6.389059595614734
214,term investments,6.379545454545455
215,stock options,6.375490196078432
216,warrant liability,6.368484794448283
217,facility lease obligation,6.36010101010101
218,nol carryforwards,6.355121293800539
219,cellular growth,6.345054945054946
220,dilution feature,6.344827586206897
221,money market funds,6.338709677419355
222,stock warrants,6.306265664160401
223,debt financing transactions,6.291666666666666
224,net loss,6.2793549852373385
225,tiered royalties,6.277777777777778
226,negative evidence,6.277777777777778
227,expenses,6.272610699258665
228,clinical trials,6.258683683683683
229,deferred revenue,6.246212314586347
230,year lease,6.234967320261438
231,significant estimates,6.222222222222221
232,unvested options,6.206547619047619
233,forfeiture rate,6.200877192982456
234,accounting analysis,6.198458352508053
235,nol carryforwards,6.192857142857143
236,material losses,6.1829761175750155
237,total investments,6.1650717703349285
238,lease expense,6.16235167206041
239,notes thereto,6.158974358974359
240,additional disclosure,6.154351395730706
241,therapeutic candidates,6.137142857142857
242,significant delays,6.133333333333334
243,actual forfeitures,6.115617715617716
244,net proceeds,6.089635854341736
245,net consists primarily,6.082869767625359
246,market development work,6.078354647833556
247,product revenue,6.067857142857143
248,amounts,6.04225352112676
249,development activities,6.035297144327245
250,milestone payments,6.021144278606965
251,stock option,6.0101760892150295
252,state income taxes,6.003156146179402
253,cost sharing revenue,5.996252204585538
254,actual forfeitures,5.993395493395494
255,celgene collaboration arrangement,5.992880863428809
256,trial operations,5.980117454174058
257,transfers,5.977852348993289
258,outstanding warrants,5.961305248232243
259,related notes,5.954626532887403
260,operating loss,5.946021651904005
261,based payments,5.9339726174896885
262,reported amounts,5.867948717948718
263,stock option activity,5.827077497665734
264,investment policy,5.787784679089027
265,comprehensive loss,5.7867613376087945
266,balance sheet,5.757309941520468
267,indemnification agreements,5.746904024767802
268,sale debt securities,5.742075005372878
269,development costs,5.72235441782953
270,celgene jointly develop,5.6837899543379
271,toxicology studies,5.656240369799692
272,luspatercept expenses,5.6547363031234
273,business acceleron,5.607771260997067
274,risk mds,5.6037037037037045
275,term investments,5.548663101604278
276,cost basis,5.545938921377518
277,companies,5.48345824816413
278,management,5.441441441441441
279,events,5.414633958188691
280,net cash,5.402956885375551
281,development costs,5.385233205708319
282,research technology company,5.366043303767158
283,reasonable estimates,5.355555555555555
284,research,5.354794450533693
285,commercialization costs,5.327537033622226
286,administrative expenses,5.325516217653314
287,luspatercept program,5.3167608286252355
288,twelve months,5.307556080283353
289,warrants,5.262454699941081
290,stock,5.2366758784050536
291,regulatory approval,5.199999999999999
292,innovative therapeutics,5.177884615384615
293,valuation allowance,5.134920634920634
294,accounting pronouncements,5.1248185776487665
295,amounts,5.052100840336134
296,tax positions,5.034653465346535
297,executive officer,5.017857142857142
298,licensed technology,5.0
299,regulatory approvals,5.0
300,unrealized gains,4.989130434782609
301,consolidated statements,4.981460674157303
302,classified warrants,4.9665113008766255
303,milestone payment,4.916666666666666
304,deferred taxes,4.905279503105589
305,capital,4.8982479784366575
306,tax position,4.867986798679868
307,public offering,4.85531914893617
308,drug application,4.830952380952381
309,capital requirements,4.816940987555199
310,clinical trial,4.8165954415954415
311,foreign jurisdictions,4.8125
312,innovative therapies,4.8125
313,deferred revenue,4.812422360248447
314,development milestones,4.811073541842773
315,research activities,4.785249778303281
316,future year,4.781419234360412
317,clinical trials,4.780905905905906
318,additional capital,4.77878985035784
319,tooth disease,4.777777777777778
320,current period,4.7738239873012
321,unvested options,4.769047619047619
322,future compounds,4.753968253968254
323,additional debt,4.719827586206897
324,common stock,4.704761904761905
325,milestones,4.695801066942007
326,preferred stock,4.692156862745098
327,capital resources,4.683962264150944
328,recently issued,4.683098591549296
329,financial position,4.67948717948718
330,measurement,4.678571428571429
331,phase3 study,4.666666666666666
332,significant uncertainty,4.666666666666666
333,accounting policy,4.652291105121294
334,single arrangement,4.65
335,tax expense,4.641449581851389
336,therapeutic candidates,4.637142857142857
337,significant change,4.628930817610063
338,human body,4.625
339,financial resources,4.596153846153847
340,additional funding,4.594827586206897
341,data,4.583333333333334
342,therapeutic candidate,4.578571428571429
343,expenses,4.576958525345622
344,facioscapulohumeral dystrophy,4.571428571428571
345,financial instruments,4.568376068376068
346,stock compensation,4.5620198764437285
347,collaboration arrangement,4.559090909090909
348,transition method,4.555555555555555
349,toxicology studies,4.554545454545455
350,diluted net,4.540616246498599
351,based compensation,4.538980660757454
352,tax examinations,4.534653465346535
353,fully vested,4.533333333333333
354,forfeiture rate,4.516666666666667
355,financial assets,4.508653846153846
356,tax benefits,4.500170706725845
357,proprietary technology,4.5
358,similar expressions,4.5
359,lead program,4.5
360,specific tasks,4.5
361,litigation,4.5
362,financial statements,4.496153846153846
363,operating assets,4.495833333333334
364,accounting change,4.471698113207547
365,prior year,4.466844919786096
366,provision,4.444444444444445
367,sublicensing revenue,4.442857142857143
368,stock ownership,4.442156862745098
369,protein,4.434782608695652
370,protein homeostasis,4.434782608695652
371,capital preservation,4.433962264150944
372,facility expenses,4.431503979891077
373,toxicology expenses,4.431503979891077
374,interim periods,4.420289855072464
375,contractual obligations,4.411764705882353
376,regulatory authority,4.4
377,modified agreements,4.398864809081528
378,clinical utility,4.393518518518519
379,clinical programs,4.393518518518519
380,clinical sites,4.393518518518519
381,procuring clinical,4.393518518518519
382,nol carryforwards,4.392857142857142
383,cash,4.39135548368127
384,risks,4.387605042016807
385,risks,4.375
386,debt financings,4.375
387,drug administration,4.366666666666667
388,valuation methodology,4.357142857142858
389,financial condition,4.346153846153847
390,financial institutions,4.346153846153847
391,financial asset,4.346153846153847
392,cellular growth,4.345054945054946
393,additional programs,4.344827586206897
394,additional activities,4.344827586206897
395,decisions,4.333333333333334
396,operating segment,4.333333333333334
397,operating activities,4.333333333333334
398,operating restrictions,4.333333333333334
399,significant stockholders,4.333333333333333
400,independently developing,4.329032258064516
401,accounting standard,4.313355530891602
402,expenses,4.310291858678956
403,investment policy,4.309523809523809
404,lease commences,4.305555555555555
405,lease,4.305555555555555
406,upfront payments,4.304477611940299
407,inflammatory diseases,4.302631578947368
408,related subjects,4.2956521739130435
409,related activities,4.2956521739130435
410,key personnel,4.291666666666667
411,clinical supplies,4.277239448751077
412,exercise price,4.273752012882448
413,based payments,4.273595258999122
414,related expenses,4.272610699258665
415,expenses,4.272610699258665
416,milestone payments,4.271144278606965
417,revenue,4.267857142857143
418,initial recognition,4.257352941176471
419,public investors,4.25531914893617
420,public offerings,4.25531914893617
421,asu requires,4.25516693163752
422,jointly develop,4.25
423,platform technology,4.25
424,exchange,4.25
425,exchange commission,4.25
426,forfeitures,4.230769230769231
427,significant estimates,4.222222222222222
428,existing asset,4.222222222222222
429,losses,4.220657276995305
430,patent rights,4.217391304347826
431,state jurisdictions,4.2
432,preclinical studies,4.196153846153846
433,thereto,4.1923076923076925
434,future payments,4.191779199241886
435,vested options,4.183333333333334
436,stock options,4.175490196078432
437,stock options,4.175490196078432
438,accompanying notes,4.175066312997347
439,product sales,4.1745283018867925
440,year period,4.170588235294118
441,milestone revenues,4.166666666666666
442,financing activities,4.166666666666666
443,contingent assets,4.1625
444,values assets,4.1625
445,lived assets,4.1625
446,earnings,4.158730158730159
447,3 acceleron,4.153225806451613
448,4 acceleron,4.153225806451613
449,5 acceleron,4.153225806451613
450,lab supplies,4.1503875968992245
451,amounts,4.15
452,adopting asu 2016,4.147058823529411
453,adopting asu 2017,4.147058823529411
454,lower expenses,4.143625192012289
455,policy election,4.142857142857142
456,reconciling beginning,4.142857142857142
457,interest income,4.142441860465116
458,milestone,4.133333333333333
459,administrative expenses,4.133208525345622
460,clinical development,4.13316348893272
461,investments debt,4.129545454545455
462,remain outstanding,4.129032258064516
463,specific guidance,4.125
464,based awards,4.121498599439776
465,additional costs,4.1154158215010135
466,financial instrument,4.115384615384615
467,early adoption,4.114634146341464
468,continued growth,4.114285714285714
469,common warrants,4.114108801415303
470,credit risk,4.112037037037037
471,milestone revenue,4.109523809523809
472,amortization/interest expense,4.106796116504855
473,aggregate intrinsic,4.103448275862069
474,royalty,4.102981029810298
475,quarterly report,4.1
476,standard related,4.099573742540494
477,securities,4.098989898989899
478,compensation cost,4.098258075427025
479,preclinical activities,4.096153846153847
480,preclinical programs,4.096153846153847
481,total proceeds,4.0928792569659445
482,foreseeable future,4.087301587301587
483,credit cards,4.075
484,clinical services,4.06743156199678
485,related costs,4.066240409207161
486,accrued expenses,4.060291858678956
487,cost sharing,4.053395061728395
488,rare diseases,4.052631578947368
489,historical experience,4.05
490,consolidation requirements,4.049645390070922
491,related disclosures,4.0456521739130435
492,driven primarily,4.04225352112676
493,primarily composed,4.04225352112676
494,legal services,4.031055900621118
495,commercial supplies,4.03077975376197
496,periods,4.028985507246377
497,additional services,4.0187406296851576
498,future sales,4.01182988918838
499,data,4.0025641025641026
500,profitability,4.0
501,government regulations,4.0
502,united states,4.0
503,necessarily indicative,4.0
504,marketable security,4.0
505,temporary impairments,4.0
506,tables,4.0
507,input,4.0
508,table sets,4.0
509,remaining life,4.0
510,eligible asset,4.0
511,technical merits,4.0
512,simplification,4.0
513,physical settlement,4.0
514,litigation,4.0
515,holds harmless,4.0
516,lawsuits,4.0
517,myelodysplastic syndromes,4.0
518,sample testing,4.0
519,molecules,4.0
520,table,4.0
521,variations thereon,4.0
522,competitive dynamics,4.0
523,shorter timelines,4.0
524,press releases,4.0
525,bone disorder,4.0
526,vascular calcification,4.0
527,healthy volunteers,4.0
528,muscles,4.0
529,activities,4.0
530,venture investors,4.0
531,significantly delay,4.0
532,scale back,4.0
533,profitable depends,4.0
534,promotion activities,4.0
535,direct employee,4.0
536,investigative sites,4.0
537,government regulation,4.0
538,pricing models,4.0
539,values,4.0
540,readily apparent,4.0
541,rights,4.0
542,incur indebtedness,4.0
543,potentially impair,4.0
544,significantly harm,4.0
545,rulesand regulations,4.0
546,generation solutions,4.0
547,amounts,4.0
548,temporary differences,4.0
549,sidney street,4.0
550,sidney street,4.0
551,square feet,4.0
552,erie street,4.0
553,optional contribution,4.0
554,development funding,3.989644970414201
555,product development,3.989644970414201
556,tax benefit,3.986266368572341
557,underlying options,3.9833333333333334
558,options,3.9833333333333334
559,existing cash,3.9819987585350716
560,based vesting,3.9816176470588234
561,company,3.977852348993289
562,miscellaneous expenses,3.976958525345622
563,related services,3.9695652173913043
564,current reports,3.9680851063829787
565,measurement,3.9642857142857144
566,credit losses,3.962323943661972
567,future,3.9623015873015874
568,accounting analysis,3.9484583525080534
569,initial date,3.9431818181818183
570,indemnification agreements,3.942982456140351
571,ongoing activities,3.928571428571429
572,proprietary knowledge,3.916666666666667
573,historical trends,3.916666666666667
574,50% reduced rate,3.916666666666667
575,financing transactions,3.9166666666666665
576,license,3.9166666666666665
577,milestone,3.9166666666666665
578,investment portfolio,3.9166666666666665
579,existing agreements,3.9152046783625734
580,standard,3.9120296767355587
581,lease obligation,3.9055555555555554
582,acceleron files,3.903225806451613
583,annual periods,3.9004140786749484
584,regulatory compliance,3.9
585,marketable securities,3.898989898989899
586,securities,3.898989898989899
587,securities,3.898989898989899
588,personnel expense,3.898462783171521
589,share data,3.8937106918238995
590,existing stockholders,3.8888888888888893
591,adopted prospectively,3.888888888888889
592,collection losses,3.887323943661972
593,losses,3.887323943661972
594,losses,3.887323943661972
595,numerous risks,3.875
596,revenues,3.875
597,risks incident,3.875
598,risks,3.875
599,risks,3.875
600,annual report,3.8714285714285714
601,annual limitation,3.8714285714285714
602,future products,3.8699102829537613
603,cash equivalents,3.8691515363128492
604,amortized cost,3.8617283950617285
605,tax years,3.8607404218682735
606,periods,3.8582537999293036
607,legal entities,3.857142857142857
608,losses,3.8539906103286383
609,expenses,3.851958525345622
610,collaboration revenue,3.8519480519480522
611,existing guidance,3.8472222222222223
612,development expense,3.8464410869190555
613,development payments,3.8441225823544998
614,market acceptance,3.838709677419355
615,future partners,3.8373015873015874
616,adjustment,3.835164835164835
617,cumulative adjustment,3.835164835164835
618,primary sources,3.833333333333333
619,presented separately,3.8292682926829267
620,stock option,3.827077497665733
621,share lower,3.8270440251572326
622,future development,3.8269465577157886
623,based rsus,3.826260504201681
624,revenue recognition,3.825210084033613
625,credit,3.825
626,credit,3.825
627,generally perpetual,3.8235294117647056
628,expense,3.8230123327210705
629,revenue,3.817857142857143
630,credit loss,3.813738738738739
631,fully offset,3.8133333333333335
632,activities,3.8125
633,company,3.811185682326622
634,company,3.811185682326622
635,potential benefits,3.808654496281271
636,warrant agreement,3.8072223730654358
637,standard shortens,3.803921568627451
638,income taxes,3.803156146179402
639,primarily cash,3.8020300574396098
640,periods,3.8017127799736494
641,prior periods,3.8017127799736494
642,net sales,3.7984778817187252
643,amount,3.793103448275862
644,commercial license,3.7859477124183005
645,products,3.782608695652174
646,approved products,3.782608695652174
647,dilutive effect,3.7777777777777777
648,key terms,3.7777777777777777
649,external costs,3.7705882352941176
650,costs,3.7705882352941176
651,milestone events,3.7701149425287355
652,underlying instrument,3.769230769230769
653,personnel expenses,3.768625192012289
654,leases,3.765765765765766
655,royalty payments,3.763014197306152
656,incurred losses,3.762323943661972
657,losses,3.762323943661972
658,cash flows,3.7597765363128492
659,primarily due,3.7584697373429767
660,net proceeds,3.7563025210084033
661,future trends,3.753968253968254
662,substantially accurate,3.75
663,resources,3.75
664,matters,3.75
665,footnote disclosures,3.75
666,efficiently identify,3.75
667,subsequent events,3.7463054187192117
668,collaboration arrangements,3.742424242424242
669,development expertise,3.739644970414201
670,development platform,3.739644970414201
671,joint development,3.739644970414201
672,development activities,3.739644970414201
673,assay development,3.739644970414201
674,development efforts,3.739644970414201
675,patents,3.736842105263158
676,patents,3.736842105263158
677,recognized based,3.73578431372549
678,preclinical research,3.7343448009277154
679,options,3.7333333333333334
680,public company,3.733171497929459
681,outstanding warrants,3.730536017463012
682,development expenses,3.7166034957598235
683,manufacturing preclinical,3.7161538461538464
684,primarily funded,3.708920187793427
685,treasury notes,3.6923076923076925
686,developing estimates,3.6845878136200714
687,services,3.6739130434782608
688,consulting agreement,3.669291338582677
689,management,3.666666666666667
690,evidence,3.666666666666667
691,management,3.666666666666667
692,level3 inputs,3.666666666666667
693,north america,3.666666666666667
694,differ materially,3.666666666666667
695,allocated facilities,3.666666666666667
696,judgments,3.666666666666667
697,company,3.660950940542585
698,company,3.660950940542585
699,company,3.660950940542585
700,company,3.660950940542585
701,employee share,3.660377358490566
702,collaboration partners,3.659090909090909
703,royalty schedules,3.6585365853658534
704,existing leases,3.6546546546546548
705,remaining weighted,3.653846153846154
706,statements,3.65
707,equity offerings,3.6493506493506493
708,comprehensive income,3.648797792668506
709,incurred costs,3.6455882352941176
710,costs,3.6455882352941176
711,collateral,3.642857142857143
712,principally relating,3.642857142857143
713,subsequent phase,3.642857142857143
714,net income,3.641391440297049
715,licensable license,3.638888888888889
716,research,3.6381909547738696
717,outsourced research,3.6381909547738696
718,external research,3.6381909547738696
719,continued research,3.6381909547738696
720,miscellaneous research,3.6381909547738696
721,accounting treatment,3.6376390904692792
722,net cash,3.633726116144782
723,level3 measurement,3.630952380952381
724,additional information,3.6305418719211824
725,statements,3.628260869565217
726,applicable guidance,3.625
727,collaboration reimbursement,3.6233766233766236
728,comprehensive loss,3.6200946709421284
729,manufacturing capabilities,3.62
730,research,3.6151494801194914
731,commercial sale,3.6151439299123904
732,ongoing basis,3.612781954887218
733,net loss,3.6126883185706715
734,continuing operations,3.607966457023061
735,developing luspatercept,3.606810035842294
736,prior arrangements,3.606060606060606
737,unanticipated events,3.603448275862069
738,collaboration agreements,3.60207336523126
739,equity awards,3.6017316017316015
740,applicable warrants,3.601503759398496
741,professional fees,3.6
742,nonrefundable fees,3.6
743,rentable office,3.6
744,leases,3.599099099099099
745,potential development,3.582782225316162
746,amortization expense,3.58048032703117
747,collaboration agreement,3.578382247673586
748,amounts,3.569230769230769
749,material,3.5666666666666664
750,discovery efforts,3.564516129032258
751,future period,3.5637721755368816
752,net basis,3.558160106147722
753,lowest level,3.5555555555555554
754,substantially completed,3.55
755,equity securities,3.5483405483405486
756,securities,3.546048722519311
757,material impact,3.541666666666667
758,adversely impact,3.541666666666667
759,measurement date,3.5324675324675323
760,development personnel,3.5313116370808677
761,stock,3.531139913592556
762,actual results,3.5181818181818185
763,net research,3.512140534605802
764,purchase shares,3.5108695652173916
765,development costs,3.5102332057083188
766,revenue,3.5095238095238095
767,revenue,3.5095238095238095
768,patent expiration,3.5031055900621118
769,gains,3.5
770,transfers goods,3.5
771,identifies areas,3.5
772,indemnified party,3.5
773,words,3.5
774,molecule,3.5
775,potentially begin,3.5
776,compliance,3.5
777,dividend yield,3.5
778,adversely affect,3.5
779,identifies areas,3.5
780,collaboration receivables,3.497326203208556
781,estimated amounts,3.484210526315789
782,partially offset,3.48
783,company,3.477852348993289
784,company records,3.477852348993289
785,company,3.477852348993289
786,company adjusts,3.477852348993289
787,company,3.477852348993289
788,company,3.477852348993289
789,company,3.477852348993289
790,company,3.477852348993289
791,company indemnifies,3.477852348993289
792,company,3.477852348993289
793,company,3.477852348993289
794,company,3.477852348993289
795,company,3.477852348993289
796,leading company,3.477852348993289
797,company,3.477852348993289
798,company files,3.477852348993289
799,promote luspatercept,3.477777777777778
800,travel expenses,3.476958525345622
801,period,3.476470588235294
802,average period,3.476470588235294
803,comparable period,3.476470588235294
804,profit institution,3.473684210526316
805,current expectations,3.4680851063829787
806,share amounts,3.4603773584905664
807,event,3.4545454545454546
808,temporary impairment,3.4444444444444446
809,services,3.44314381270903
810,amendment,3.441441441441441
811,facilities costs,3.4372549019607845
812,celgene corporation,3.4337899543378994
813,celgene,3.4337899543378994
814,celgene,3.4337899543378994
815,celgene,3.4337899543378994
816,future performance,3.432129173508484
817,rent,3.428571428571429
818,matters,3.416666666666667
819,mid 20% range,3.4117647058823533
820,equity investments,3.4038961038961038
821,option contracts,3.384920634920635
822,potential impact,3.3848039215686274
823,predominantly derived,3.3846153846153846
824,recognize revenue,3.380357142857143
825,term investments,3.379545454545455
826,developing sotatercept,3.3772074405462678
827,primarily attributable,3.375586854460094
828,underwriting discounts,3.375
829,reimburse collaborators,3.375
830,sale securities,3.367075005372878
831,company,3.3667412378821773
832,company,3.360205290169759
833,reasonable estimates,3.3555555555555556
834,reasonable estimates,3.3555555555555556
835,events,3.353448275862069
836,royalties,3.349206349206349
837,net amortization,3.3476337903582483
838,assess performance,3.344827586206897
839,commercialization,3.344827586206897
840,0 million held,3.3351851851851855
841,8 million held,3.3351851851851855
842,estimation process,3.333333333333333
843,owner sources,3.333333333333333
844,uncertainties,3.333333333333333
845,activities,3.333333333333333
846,accumulated deficit,3.333333333333333
847,uncertainties,3.333333333333333
848,license agreements,3.3318713450292394
849,commercial operations,3.310580836108028
850,risk factors,3.3097643097643097
851,license agreement,3.308180227471566
852,option agreement,3.304211973503312
853,biotechnology industry,3.3
854,sufficient amounts,3.3
855,measurement gain,3.2976190476190474
856,sufficient amount,3.293103448275862
857,period,3.288970588235294
858,low single,3.2857142857142856
859,company,3.2778523489932887
860,favorable terms,3.2777777777777777
861,terms,3.2777777777777777
862,reasonable period,3.276470588235294
863,entity,3.2727272727272725
864,average assumptions,3.2727272727272725
865,subjective assumptions,3.2727272727272725
866,unknown factors,3.2727272727272725
867,license,3.263888888888889
868,shares,3.2608695652173916
869,aggregate fair,3.256389452332657
870,asc topic815,3.25
871,read carefully,3.25
872,item,3.25
873,classified warrants,3.248562582927908
874,warrants,3.248562582927908
875,promote sotatercept,3.2481751824817517
876,items,3.238095238095238
877,original date,3.234848484848485
878,immediately exercisable,3.2272727272727275
879,beta,3.2222222222222223
880,exclusive rights,3.217391304347826
881,business partners,3.2045454545454546
882,economic circumstances,3.2
883,retrospectively adjusted,3.2
884,potentially subject,3.196078431372549
885,company,3.1958010669420065
886,company,3.1958010669420065
887,company,3.1958010669420065
888,commercialize luspatercept,3.1920634920634923
889,potential commercialization,3.1879648411088573
890,celgene,3.1837899543378994
891,luspatercept agreements,3.170760233918129
892,original maturities,3.166666666666667
893,individual customers,3.166666666666667
894,bring forward,3.166666666666667
895,estimated period,3.1606811145510836
896,income statement,3.160299003322259
897,luspatercept agreement,3.1470691163604547
898,luspatercept agreement,3.1470691163604547
899,fees,3.1454545454545455
900,extent,3.1315789473684212
901,celgene agreements,3.1267724104782504
902,company,3.1207094918504312
903,commercialization costs,3.1154158215010144
904,research institution,3.111875165300185
905,consolidation analysis,3.105691056910569
906,royalty rates,3.102981029810298
907,company,3.102852348993289
908,million change,3.097449336128581
909,generated exclusively,3.0869565217391304
910,liabilities,3.082191780821918
911,advance ace,3.064102564102564
912,rsus vest,3.057142857142857
913,estimates,3.0555555555555554
914,increase substantially,3.0543478260869565
915,material,3.051282051282051
916,milestones,3.0454545454545454
917,company,3.0445190156599553
918,company,3.0445190156599553
919,classified statement,3.0399159663865545
920,premium amortization,3.0292397660818713
921,research,3.0228063393892537
922,generally subject,3.019607843137255
923,considered probable,3.0
924,proceeds,3.0
925,fair market,2.9916508538899427
926,support development,2.989644970414201
927,dalantercept,2.985294117647059
928,company,2.977852348993289
929,manufacture luspatercept,2.977777777777778
930,commercialize sotatercept,2.9624608967674657
931,business enterprise,2.9545454545454546
932,amortization period,2.95015479876161
933,dalantercept,2.9495798319327733
934,development progress,2.939644970414201
935,completion costs,2.9372549019607845
936,sotatercept agreement,2.917466521064429
937,identify forward,2.916666666666667
938,personnel,2.893361581920904
939,business,2.8920454545454546
940,results,2.8666666666666667
941,premium,2.8632478632478633
942,date,2.853896103896104
943,6 million due,2.851401401401401
944,estimates,2.8412698412698414
945,estimated fair,2.8371517027863775
946,party cros,2.7941176470588234
947,operations,2.7885220125786163
948,company,2.7855446566855964
949,million relating,2.7780423280423276
950,company,2.7635666347075745
951,current assumptions,2.7408123791102517
952,discount,2.7222222222222223
953,effective date,2.7220279720279716
954,year,2.6941176470588237
955,salaries,2.6723163841807906
956,company,2.6693417106954165
957,company,2.6596705308114705
958,issuance date,2.656417112299465
959,anemia,2.6527777777777777
960,company,2.6445190156599554
961,dalantercept,2.592436974789916
962,celgene responsible,2.5653689017063206
963,time period,2.55222816399287
964,fair presentation,2.5375565610859727
965,tax,2.5346534653465347
966,million decrease,2.525429087624209
967,million decrease,2.525429087624209
968,million decrease,2.525429087624209
969,million decrease,2.525429087624209
970,million decrease,2.525429087624209
971,patients,2.525
972,accounting,2.509433962264151
973,application,2.4642857142857144
974,raise,2.4642857142857144
975,million increase,2.4395330112721414
976,million increase,2.4395330112721414
977,million increase,2.4395330112721414
978,million increase,2.4395330112721414
979,million increase,2.4395330112721414
980,million increase,2.4395330112721414
981,million increase,2.4395330112721414
982,million increase,2.4395330112721414
983,million increase,2.4395330112721414
984,million increase,2.4395330112721414
985,trial,2.423076923076923
986,regulatory,2.4
987,permitted,2.4
988,cambridge massachusetts,2.4
989,clinical,2.3935185185185186
990,interim,2.391304347826087
991,trials,2.3873873873873874
992,requirements,2.382978723404255
993,interest,2.375
994,compensation,2.3698630136986303
995,drug,2.3666666666666667
996,valuation,2.357142857142857
997,legal,2.357142857142857
998,price,2.347826086956522
999,additional $545,2.3448275862068964
1000,additional,2.3448275862068964
1001,operating,2.3333333333333335
1002,critical,2.3333333333333335
1003,section382,2.3333333333333335
1004,sharing,2.325
1005,lease,2.3055555555555554
1006,related,2.2956521739130435
1007,000 related,2.2956521739130435
1008,purchase,2.25
1009,purchase,2.25
1010,candidate,2.25
1011,carryforwards,2.25
1012,ownership,2.25
1013,space,2.25
1014,substantial,2.230769230769231
1015,forfeitures,2.230769230769231
1016,june30,2.226993865030675
1017,method,2.2222222222222223
1018,patent,2.217391304347826
1019,september30,2.2142857142857144
1020,worldwide,2.212121212121212
1021,total,2.210526315789474
1022,state,2.2
1023,2016 increased,2.2
1024,held,2.2
1025,stock,2.1921568627450982
1026,issued,2.183098591549296
1027,000 issued,2.183098591549296
1028,based,2.1691176470588234
1029,consists,2.1666666666666665
1030,financing,2.1666666666666665
1031,phase3,2.1666666666666665
1032,licensing,2.1666666666666665
1033,milestone,2.1666666666666665
1034,assets,2.1625
1035,statements,2.15
1036,asu,2.1470588235294117
1037,subsequent,2.142857142857143
1038,beginning,2.142857142857143
1039,require,2.142857142857143
1040,executive,2.142857142857143
1041,nol,2.142857142857143
1042,cumulative,2.142857142857143
1043,march31,2.13986013986014
1044,warrant,2.1379310344827585
1045,amortized,2.1333333333333333
1046,developing,2.129032258064516
1047,outstanding,2.129032258064516
1048,growth,2.1142857142857143
1049,02 requires,2.108108108108108
1050,expense,2.1067961165048543
1051,payments,2.1044776119402986
1052,aggregate,2.103448275862069
1053,studies,2.1
1054,preclinical,2.0961538461538463
1055,fasb,2.090909090909091
1056,future,2.0873015873015874
1057,credit,2.075
1058,conduct,2.0555555555555554
1059,primarily,2.0422535211267605
1060,risk,2.037037037037037
1061,taxes,2.0357142857142856
1062,periods,2.028985507246377
1063,regulate,2.0
1064,gaap,2.0
1065,adjustments,2.0
1066,identified,2.0
1067,carried,2.0
1068,premiums,2.0
1069,evidence,2.0
1070,institutions,2.0
1071,transfers,2.0
1072,inputs,2.0
1073,identification,2.0
1074,asset,2.0
1075,hedging,2.0
1076,obtain,2.0
1077,material,2.0
1078,activities,2.0
1079,equivalent,2.0
1080,activity,2.0
1081,attribute,2.0
1082,negative,2.0
1083,underlying,2.0
1084,approved,2.0
1085,seek,2.0
1086,potentially,2.0
1087,insurance,2.0
1088,incur,2.0
1089,dilution,2.0
1090,utilize,2.0
1091,defending,2.0
1092,rent,2.0
1093,options,1.9833333333333334
1094,expenses,1.976958525345622
1095,included,1.9666666666666666
1096,benefits,1.9655172413793103
1097,change,1.9622641509433962
1098,awards,1.9523809523809523
1099,revenue,1.9428571428571428
1100,2015 revenue,1.9428571428571428
1101,2016 revenue,1.9428571428571428
1102,update,1.9333333333333333
1103,ongoing,1.9285714285714286
1104,exercise,1.9259259259259258
1105,sales,1.9245283018867925
1106,rate,1.9166666666666667
1107,collaboration,1.9090909090909092
1108,acceleron,1.903225806451613
1109,securities,1.898989898989899
1110,adopted,1.8888888888888888
1111,excess,1.8888888888888888
1112,losses,1.8873239436619718
1113,supplies,1.8837209302325582
1114,proceeds,1.8823529411764706
1115,expects,1.8823529411764706
1116,recognition,1.8823529411764706
1117,comprehensive,1.88135593220339
1118,december31,1.8759124087591241
1119,risks,1.875
1120,incurred,1.875
1121,generate,1.875
1122,net,1.8739495798319328
1123,annual,1.8714285714285714
1124,develop,1.85
1125,potential,1.8431372549019607
1126,market,1.8387096774193548
1127,arrangements,1.8333333333333333
1128,presented,1.829268292682927
1129,generally,1.8235294117647058
1130,vesting,1.8125
1131,investing,1.8125
1132,standard,1.803921568627451
1133,amounts,1.8
1134,reasonable,1.8
1135,federal,1.8
1136,experience,1.8
1137,completed,1.8
1138,amount,1.793103448275862
1139,personnel,1.7916666666666667
1140,products,1.7826086956521738
1141,royalties,1.7777777777777777
1142,effect,1.7777777777777777
1143,prior,1.7727272727272727
1144,costs,1.7705882352941176
1145,life,1.7692307692307692
1146,instrument,1.7692307692307692
1147,provided,1.7692307692307692
1148,income,1.7674418604651163
1149,cash,1.7597765363128492
1150,investments,1.7545454545454546
1151,reflect,1.75
1152,transactions,1.75
1153,contracts,1.75
1154,substantially,1.75
1155,granted,1.75
1156,totaling $4,1.75
1157,anticipated,1.75
1158,disclosures,1.75
1159,identify,1.75
1160,partners,1.75
1161,2016 totaling $0,1.75
1162,development,1.7396449704142012
1163,loss,1.7387387387387387
1164,patents,1.736842105263158
1165,cost,1.728395061728395
1166,liability,1.7179487179487178
1167,expensed,1.7179487179487178
1168,due,1.7162162162162162
1169,provisions,1.7142857142857142
1170,commercialize,1.7142857142857142
1171,reimbursement,1.7142857142857142
1172,agreements,1.6929824561403508
1173,notes,1.6923076923076923
1174,adjustment,1.6923076923076923
1175,basis,1.6842105263157894
1176,estimated,1.6842105263157894
1177,services,1.673913043478261
1178,agreement,1.669291338582677
1179,america,1.6666666666666667
1180,disclosure,1.6666666666666667
1181,stockholders,1.6666666666666667
1182,level3,1.6666666666666667
1183,considered,1.6666666666666667
1184,consolidation,1.6666666666666667
1185,knowledge,1.6666666666666667
1186,original,1.6666666666666667
1187,funded,1.6666666666666667
1188,facilities,1.6666666666666667
1189,trends,1.6666666666666667
1190,differ,1.6666666666666667
1191,delays,1.6666666666666667
1192,share,1.6603773584905661
1193,royalty,1.6585365853658536
1194,980 rsus,1.6571428571428573
1195,rsus,1.6571428571428573
1196,692 rsus,1.6571428571428573
1197,equity,1.6493506493506493
1198,classified,1.6470588235294117
1199,relating,1.6428571428571428
1200,agreed,1.6428571428571428
1201,license,1.6388888888888888
1202,research,1.6381909547738693
1203,option,1.6349206349206349
1204,term,1.625
1205,guidance,1.625
1206,includes,1.625
1207,23 comparison,1.625
1208,manufacturing,1.62
1209,events,1.603448275862069
1210,warrants,1.6015037593984962
1211,obligation,1.6
1212,fees,1.6
1213,office,1.6
1214,receivables,1.588235294117647
1215,plan,1.588235294117647
1216,companies,1.5714285714285714
1217,pay,1.5714285714285714
1218,pay $25,1.5714285714285714
1219,date,1.5681818181818181
1220,recognized,1.5666666666666667
1221,discovery,1.564516129032258
1222,estimates,1.5555555555555556
1223,level,1.5555555555555556
1224,premium,1.5555555555555556
1225,defined,1.5454545454545454
1226,impact,1.5416666666666667
1227,compliance,1.5
1228,contained,1.5
1229,affect,1.5
1230,yield,1.5
1231,areas,1.5
1232,enterprise,1.5
1233,maturities,1.5
1234,collateral,1.5
1235,money,1.5
1236,receive,1.5
1237,goods,1.5
1238,entities,1.5
1239,party,1.5
1240,milestones,1.5
1241,manufacture,1.5
1242,phase,1.5
1243,concluded,1.5
1244,words,1.5
1245,intellitrap,1.5
1246,travel,1.5
1247,allocate,1.5
1248,sufficient,1.5
1249,begin,1.5
1250,continues,1.5
1251,offset,1.48
1252,pursuant,1.4782608695652173
1253,company,1.4778523489932887
1254,luspatercept,1.4777777777777779
1255,period,1.4764705882352942
1256,amortization,1.4736842105263157
1257,institution,1.4736842105263157
1258,sale,1.4680851063829787
1259,current,1.4680851063829787
1260,business,1.4545454545454546
1261,event,1.4545454545454546
1262,benefit,1.4516129032258065
1263,impairment,1.4444444444444444
1264,earnings,1.4444444444444444
1265,rates,1.4444444444444444
1266,record,1.4444444444444444
1267,analysis,1.4390243902439024
1268,expected,1.4375
1269,recognize,1.4375
1270,celgene,1.4337899543378996
1271,leases,1.4324324324324325
1272,include,1.4285714285714286
1273,2015 include,1.4285714285714286
1274,weighted,1.4230769230769231
1275,discussed,1.4166666666666667
1276,adoption,1.4146341463414633
1277,range,1.411764705882353
1278,vest,1.4
1279,mds,1.4
1280,sublease,1.4
1281,statement,1.3928571428571428
1282,decrease,1.3902439024390243
1283,presentation,1.3846153846153846
1284,conducting,1.3846153846153846
1285,derived,1.3846153846153846
1286,discounts,1.375
1287,reimburse,1.375
1288,treat,1.375
1289,evaluating,1.3571428571428572
1290,commercialization,1.3448275862068966
1291,required,1.3448275862068966
1292,565 performance,1.3448275862068966
1293,performance,1.3448275862068966
1294,including,1.3389830508474576
1295,management,1.3333333333333333
1296,process,1.3333333333333333
1297,accumulated,1.3333333333333333
1298,probable,1.3333333333333333
1299,gain,1.3333333333333333
1300,uncertainties,1.3333333333333333
1301,sources,1.3333333333333333
1302,performed,1.3333333333333333
1303,salaries,1.3333333333333333
1304,judgments,1.3333333333333333
1305,amendment,1.3333333333333333
1306,attributable,1.3333333333333333
1307,years,1.326086956521739
1308,paid,1.3076923076923077
1309,increase,1.3043478260869565
1310,classification,1.3
1311,industry,1.3
1312,conditions,1.3
1313,cros,1.2941176470588236
1314,evaluated,1.2857142857142858
1315,improvements,1.2857142857142858
1316,make,1.2857142857142858
1317,expiration,1.2857142857142858
1318,information,1.2857142857142858
1319,low,1.2857142857142858
1320,grant,1.2857142857142858
1321,terms,1.2777777777777777
1322,anemia,1.2777777777777777
1323,assumptions,1.2727272727272727
1324,factors,1.2727272727272727
1325,entity,1.2727272727272727
1326,000 shares,1.2608695652173914
1327,shares,1.2608695652173914
1328,317 shares,1.2608695652173914
1329,109 shares,1.2608695652173914
1330,580 shares,1.2608695652173914
1331,500 shares,1.2608695652173914
1332,187 shares,1.2608695652173914
1333,014 shares,1.2608695652173914
1334,item,1.25
1335,asc,1.25
1336,read,1.25
1337,asc 320,1.25
1338,asc 740,1.25
1339,realized,1.25
1340,amended,1.25
1341,support,1.25
1342,17 item,1.25
1343,modifications,1.25
1344,sotatercept,1.2481751824817517
1345,measured,1.2380952380952381
1346,083 measured,1.2380952380952381
1347,half,1.2352941176470589
1348,dalantercept,1.2352941176470589
1349,exercisable,1.2272727272727273
1350,beta,1.2222222222222223
1351,discount,1.2222222222222223
1352,exclusive,1.2173913043478262
1353,cambridge,1.2
1354,massachusetts,1.2
1355,results,1.2
1356,circumstances,1.2
1357,adjusted,1.2
1358,progress,1.2
1359,22 results,1.2
1360,subject,1.196078431372549
1361,general,1.1923076923076923
1362,recorded,1.1914893617021276
1363,recorded $21,1.1914893617021276
1364,determined,1.1818181818181819
1365,base,1.1818181818181819
1366,changed,1.1666666666666667
1367,customers,1.1666666666666667
1368,investigational,1.1666666666666667
1369,completion,1.1666666666666667
1370,forward,1.1666666666666667
1371,invested,1.1666666666666667
1372,operations,1.1635220125786163
1373,effective,1.1538461538461537
1374,designed,1.1538461538461537
1375,fair,1.1529411764705881
1376,patients,1.15
1377,continue,1.1470588235294117
1378,cancer,1.1428571428571428
1379,3 million,1.135185185185185
1380,0 million,1.135185185185185
1381,7 million,1.135185185185185
1382,4 million,1.135185185185185
1383,1 million,1.135185185185185
1384,9 million,1.135185185185185
1385,2 million,1.135185185185185
1386,6 million,1.135185185185185
1387,8 million,1.135185185185185
1388,5 million,1.135185185185185
1389,extent,1.131578947368421
1390,responsible,1.131578947368421
1391,treatment,1.1282051282051282
1392,received $43,1.1176470588235294
1393,received,1.1176470588235294
1394,compared,1.1016949152542372
1395,2016 compared,1.1016949152542372
1396,2017 compared,1.1016949152542372
1397,issuance,1.088235294117647
1398,generated,1.0869565217391304
1399,liabilities,1.082191780821918
1400,time,1.0757575757575757
1401,part,1.0666666666666667
1402,ace,1.064102564102564
1403,long,1.0512820512820513
1404,number,1.0294117647058822
1405,result,1.018181818181818
1406,thousands,1.0
1407,unaudited,1.0
1408,nature,1.0
1409,mechanisms,1.0
1410,repair,1.0
1411,cells,1.0
1412,tissues,1.0
1413,tgf,1.0
1414,combining,1.0
1415,built,1.0
1416,action,1.0
1417,limited,1.0
1418,relying,1.0
1419,parties,1.0
1420,dependence,1.0
1421,protection,1.0
1422,prepared,1.0
1423,conformity,1.0
1424,reference,1.0
1425,meant,1.0
1426,refer,1.0
1427,found,1.0
1428,opinion,1.0
1429,consisting,1.0
1430,conjunction,1.0
1431,discussion,1.0
1432,form 10,1.0
1433,january11,1.0
1434,commissions,1.0
1435,detailed,1.0
1436,form10,1.0
1437,preparation,1.0
1438,selecting,1.0
1439,controls,1.0
1440,addition,1.0
1441,operational,1.0
1442,sensitivity,1.0
1443,volatility,1.0
1444,representative,1.0
1445,select,1.0
1446,falls,1.0
1447,turn,1.0
1448,made,1.0
1449,preparing,1.0
1450,determination,1.0
1451,recoverability,1.0
1452,components,1.0
1453,evaluation,1.0
1454,manage,1.0
1455,component,1.0
1456,short,1.0
1457,90days,1.0
1458,acquisition,1.0
1459,banks,1.0
1460,approximates,1.0
1461,reevaluates,1.0
1462,designation,1.0
1463,hold,1.0
1464,accretion,1.0
1465,maturity,1.0
1466,dividends,1.0
1467,recoverable,1.0
1468,experienced,1.0
1469,intent,1.0
1470,sell,1.0
1471,recovery,1.0
1472,severity,1.0
1473,duration,1.0
1474,end,1.0
1475,summary,1.0
1476,form,1.0
1477,certificates,1.0
1478,deposit,1.0
1479,concentrations,1.0
1480,creditworthy,1.0
1481,quality,1.0
1482,exposure,1.0
1483,creditworthiness,1.0
1484,groups,1.0
1485,believed,1.0
1486,measurements,1.0
1487,levels,1.0
1488,hierarchy,1.0
1489,note13,1.0
1490,manner,1.0
1491,deeply,1.0
1492,black,1.0
1493,march 31,1.0
1494,elected,1.0
1495,elect,1.0
1496,measure,1.0
1497,accordance,1.0
1498,consideration,1.0
1499,facts,1.0
1500,reconciliation,1.0
1501,calculation,1.0
1502,basic,1.0
1503,excluded,1.0
1504,inclusion,1.0
1505,anti,1.0
1506,occur,1.0
1507,topic,1.0
1508,supersedes,1.0
1509,reflects,1.0
1510,january 1,1.0
1511,august 2014,1.0
1512,concern,1.0
1513,subtopic 205,1.0
1514,evaluate,1.0
1515,existence,1.0
1516,ability,1.0
1517,december15,1.0
1518,february 2015,1.0
1519,topic,1.0
1520,amendments,1.0
1521,respect,1.0
1522,perform,1.0
1523,determine,1.0
1524,consolidate,1.0
1525,types,1.0
1526,january1,1.0
1527,november 2015,1.0
1528,topic,1.0
1529,february 2016,1.0
1530,topic,1.0
1531,replaces,1.0
1532,accounted,1.0
1533,lessees,1.0
1534,lessee,1.0
1535,calculated,1.0
1536,december,1.0
1537,assessing,1.0
1538,march,1.0
1539,topic,1.0
1540,aspects,1.0
1541,resulting,1.0
1542,connection,1.0
1543,consummated,1.0
1544,details,1.0
1545,place,1.0
1546,june2010,1.0
1547,july2010,1.0
1548,derivatives,1.0
1549,asc815,1.0
1550,accreted,1.0
1551,redemption,1.0
1552,earlier,1.0
1553,commitments,1.0
1554,ordinary,1.0
1555,pending,1.0
1556,threatened,1.0
1557,met,1.0
1558,payable,1.0
1559,note15,1.0
1560,agrees,1.0
1561,copyright,1.0
1562,execution,1.0
1563,unlimited,1.0
1564,february20,1.0
1565,august2,1.0
1566,indications,1.0
1567,overseeing,1.0
1568,start,1.0
1569,phase1,1.0
1570,food,1.0
1571,thalassemia,1.0
1572,assurance,1.0
1573,december,1.0
1574,100%,1.0
1575,buy,1.0
1576,noted,1.0
1577,november 2013,1.0
1578,reimbursed,1.0
1579,represent,1.0
1580,deliverable,1.0
1581,modification,1.0
1582,delivered,1.0
1583,reduction,1.0
1584,sublicensable,1.0
1585,licenses,1.0
1586,individuals,1.0
1587,digits,1.0
1588,owe,1.0
1589,percentage,1.0
1590,profits,1.0
1591,reach,1.0
1592,obligated,1.0
1593,000 annually,1.0
1594,2013 espp,1.0
1595,employees,1.0
1596,difference,1.0
1597,represents,1.0
1598,rsu,1.0
1599,approximately $3,1.0
1600,accelerated,1.0
1601,occurrence,1.0
1602,september,1.0
1603,achievement,1.0
1604,positive,1.0
1605,realizability,1.0
1606,history,1.0
1607,examination,1.0
1608,note 15,1.0
1609,deemed,1.0
1610,anticipate,1.0
1611,contemplate,1.0
1612,estimate,1.0
1613,expect,1.0
1614,forecast,1.0
1615,goal,1.0
1616,intend,1.0
1617,predict,1.0
1618,project,1.0
1619,strategy,1.0
1620,target,1.0
1621,vision,1.0
1622,case,1.0
1623,intended,1.0
1624,things,1.0
1625,intentions,1.0
1626,beliefs,1.0
1627,projections,1.0
1628,outlook,1.0
1629,analyses,1.0
1630,timing,1.0
1631,plans,1.0
1632,enter,1.0
1633,degree,1.0
1634,quickly,1.0
1635,marketing,1.0
1636,liquidity,1.0
1637,prospects,1.0
1638,strategies,1.0
1639,relate,1.0
1640,depend,1.0
1641,longer,1.0
1642,caution,1.0
1643,guarantees,1.0
1644,operate,1.0
1645,speak,1.0
1646,undertake,1.0
1647,section,1.0
1648,understand,1.0
1649,advised,1.0
1650,consult,1.0
1651,form8,1.0
1652,website,1.0
1653,overview,1.0
1654,discovering,1.0
1655,fields,1.0
1656,medicine,1.0
1657,focused,1.0
1658,treatments,1.0
1659,partnered,1.0
1660,mechanism,1.0
1661,complications,1.0
1662,commercialized,1.0
1663,wholly,1.0
1664,volume,1.0
1665,implemented,1.0
1666,accelerating,1.0
1667,nominated,1.0
1668,distribution,1.0
1669,fund,1.0
1670,unable,1.0
1671,needed,1.0
1672,fail,1.0
1673,discontinue,1.0
1674,description,1.0
1675,acquiring,1.0
1676,depreciation,1.0
1677,maintenance,1.0
1678,obtaining,1.0
1679,vendors,1.0
1680,certainty,1.0
1681,succeed,1.0
1682,variety,1.0
1683,scope,1.0
1684,receipt,1.0
1685,outcome,1.0
1686,variables,1.0
1687,enrollment,1.0
1688,inception,1.0
1689,100%,1.0
1690,reimbursements,1.0
1691,expensing,1.0
1692,track,1.0
1693,assign,1.0
1694,contractor,1.0
1695,finance,1.0
1696,september,1.0
1697,audit,1.0
1698,sec,1.0
1699,director,1.0
1700,headcount,1.0
1701,additionally,1.0
1702,payroll,1.0
1703,determining,1.0
1704,initiation,1.0
1705,increases,1.0
1706,marking,1.0
1707,mix,1.0
1708,june2003,1.0
1709,combination,1.0
1710,view,1.0
1711,implementation,1.0
1712,began,1.0
1713,invest,1.0
1714,january 2016,1.0
1715,difficulties,1.0
1716,closing,1.0
1717,pursue,1.0
1718,covenants,1.0
1719,restrict,1.0
1720,competitiveness,1.0
1721,limitations,1.0
1722,acquire,1.0
1723,adequate,1.0
1724,vary,1.0
1725,prove,1.0
1726,wrong,1.0
1727,collaborative,1.0
1728,establish,1.0
1729,characteristics,1.0
1730,caused,1.0
1731,hiring,1.0
1732,filing,1.0
1733,enforcing,1.0
1734,businesses,1.0
1735,technologies,1.0
1736,approximately $109,1.0
1737,realize,1.0
1738,approximately $276,1.0
1739,times,1.0
1740,greater,1.0
1741,utilization,1.0
1742,pre,1.0
1743,portion,1.0
1744,control,1.0
1745,lost,1.0
1746,note 13,1.0
1747,immuno,1.0
1748,oncology,1.0
1749,epigenetics,1.0
1750,immunology,1.0
1751,neuro,1.0
1752,inflammation,1.0
1753,complete,1.0
1754,deliverables,1.0
1755,september 30,1.0
1756,note 16,1.0
1757,note 5,1.0
1758,disclosed,1.0
1759,applied,1.0
1760,relates,1.0
1761,collected,1.0
1762,november,1.0
1763,topic,1.0
1764,december,1.0
1765,march 2017,1.0
1766,subtopic 310,1.0
1767,specifically,1.0
1768,substantive,1.0
1769,consistent,1.0
1770,definition,1.0
1771,applying,1.0
1772,booked,1.0
1773,approximately $6,1.0
1774,espp,1.0
1775,18 overview,1.0
1776,myelofibrosis,1.0
1777,medalist,1.0
1778,charcot,1.0
1779,marie,1.0
1780,mri,1.0
1781,expanding,1.0
1782,approximately $136,1.0
1783,accruals,1.0
1784,approximately $339,1.0
1785,july,1.0
1786,approximately 37,1.0
1787,october,1.0
1788,ends,1.0
1789,extend,1.0
1790,sublessee,1.0
1791,approximately 11,1.0
1792,march 16,1.0
1793,approximately,1.0
1794,landlord,1.0
1795,build,1.0
1796,collateralized,1.0
1797,naming,1.0
1798,beneficiary,1.0
1799,announced,1.0
1800,discontinued,1.0
